OncLiveImmunotherapy Impact Extends to MesotheliomaOncLiveAlthough the only FDA-approved regimen for the treatment of patients with pleural malignant mesothelioma is the chemotherapy combination of pemetrexed and cisplatin, clinical trials of combinati… Continue reading
OncLiveExpert Discusses Durvalumab and Expanding Role of Immunotherapy in NSCLCOncLiveIn an interview with OncLive, Marina C. Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discussed the ev… Continue reading
Phys.OrgStudy finds how to increase the survival time of stem cellsPhys.OrgBy finding a way to increase the life of the stem cells after injections, researcher can increase their existence in the tissue, thus, might help the regeneration of the tissues… Continue reading
Hemophilia Gene Therapy – A Pipeline Analysis Report 2017 – Research and MarketsBusiness Wire (press release)Hemophilia is an inherited bleeding disorder. The gene responsible for hemophilia is present on the X chromosome and is inherited in a recessiv… Continue reading
SOTIO Completes Enrollment for Phase 3 Trial of DCVAC/PCa ImmunotherapyProstate Cancer News TodayThe Phase 3 trial evaluating the immunotherapy DCVAC/PCa in men with metastatic castration-resistant prostate cancer (mCRPC), has completed patient enrollm… Continue reading
|
FDA OKs Merck drug that prevents infection post-stem cell transplant
Reuters (Reuters) – Merck & Co Ltd’s drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday. Merck said the drug, which is expected to be … |
|
FDA OKs Merck drug that prevents infection post-stem cell transplant
Reuters (Reuters) – Merck & Co Ltd’s drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday. Merck said the drug, which is expected to be … |
|
FDA OKs Merck drug that prevents infection post-stem cell transplant
Reuters (Reuters) – Merck & Co Ltd’s drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday. Merck said the drug, which is expected to be … |